Michael M. Kitt

5.5k citations

84 papers · 4.0k indexed · h-index 33

Impact in

Internal Medicine top 1%
- Venous Thromboembolism Diagnosis and Management
Cardiology and Cardiovascular Medicine top 1%
- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases

Papers in

Cardiology and Cardiovascular Medicine 40
- Acute Myocardial Infarction Research 30
- Antiplatelet Therapy and Cardiovascular Diseases 24
Internal Medicine 6

Co-authors: Steven L. Barriere Eric J. Topol James E. Tcheng Robert A. Harrington A. Michael Lincoff Neal S. Kleiman Kristina N. Sigmon Michael R. Goldberg
Journals: The American Journal of Cardiology (9 papers)Journal of the American College of Cardiology (8 papers)Circulation (7 papers)Antimicrobial Agents and Chemotherapy (4 papers)Clinical Infectious Diseases (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Michael M. Kitt

83 papers receiving 3.8k citations

Peers

Countries citing papers authored by Michael M. Kitt

Since Specialization

Citations

This map shows the geographic impact of Michael M. Kitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael M. Kitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael M. Kitt more than expected).

Fields of papers citing papers by Michael M. Kitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael M. Kitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael M. Kitt. The network helps show where Michael M. Kitt may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael M. Kitt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael M. Kitt Line = papers co-authored together Michael M. Kitt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Single‐ and Multiple‐Dose Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, in Healthy Adults The Journal of Clinical Pharmacology ·Jesse C. Nussbaum, Azher Hussain, P. Butera, Anthony Ford, Michael M. Kitt, Edward A. O’Neill, Steven A. Smith, Gabriel Vargas, Terry O’Reilly, Chris Wynne, S. Aubrey Stoch, Marian Iwamoto	2024	4
2	Effect of AX-8, a TRPM8 Agonist, on Cough Bouts in Refractory or Unexplained Chronic Cough Patients, a Proof-of-Concept Study Research Explorer (The University of Manchester) ·John A. Smith, Olivier Poirot, Paul Marsden, Cabp Adel J. Hussein, Terence E. Taylor, Yaniv Zigel, J. Østergaard, Michael M. Kitt	2024	0
3	The discovery and development of gefapixant Autonomic Neuroscience ·Anthony Ford, Michael P. Dillon, Michael M. Kitt, Joel R. Gever	2021	10
4	A Phase 2 Study in Women with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) of the Novel P2X3 Antagonist AF-219 Neurourology and Urodynamics ·Robert Moldwin, Michael M. Kitt, Jeffrey Mangel, Vladimir L. Reinyuk, J. C. LEANDRO, P. Butera, Anthony Ford	2015	6
5	The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study American Heart Journal ·Alexander T Cohen, Robert A. Harrington, Samuel Z. Goldhaber, Russell D. Hull, C. Michael Gibson, Adrian F. Hernandez, Michael M. Kitt, Todd J. Lorenz	2013	71
6	In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia Diagnostic Microbiology and Infectious Disease ·Kevin M. Krause, Johanne Blais, Lorena Noyola Piña, Christopher S. Lunde, Steven L. Barriere, H. David Friedland, Michael M. Kitt, Bret M. Benton	2012	13
7	Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study Alimentary Pharmacology & Therapeutics ·Michael R. Goldberg, Ying Li, John F. Johanson, Allen W. Mangel, Michael M. Kitt, David T. Beattie, Kathryn Kersey, Elena Fernández-Martín	2010	86
8	Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects Journal of Antimicrobial Chemotherapy ·Shekman Wong, Steven L. Barriere, Michael M. Kitt, Michael R. Goldberg	2008	35
9	Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms Clinical Infectious Diseases ·Martín E. Stryjewski, Donald R. Graham, Samuel E. Wilson, William O’Riordan, David M. Young, Arnold Lentnek, Maali Alkadhem, Vance G. Fowler, Alan R. Hopkins, H. David Friedland, Steven L. Barriere, Michael M. Kitt, G. Ralph Corey, (unknown)	2008	236
10	Effects of a New Antibacterial, Telavancin, on Cardiac Repolarization (QTc Interval Duration) in Healthy Subjects The Journal of Clinical Pharmacology ·Steven L. Barriere, Fredric C. Genter, Elizabeth Spencer, Michael M. Kitt, David Hoelscher, Joel Morganroth	2004	52
11	Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy) The American Journal of Cardiology ·Abdallah Rebeiz, Jean‐Pierre Déry, Anastasios A. Tsiatis, J.Conor O’Shea, Brent A. Johnson, Anne S. Hellkamp, Karen S. Pieper, Ian C. Gilchrist, James Slater, Joseph B. Muhlestein, Diane Joseph‐McCarthy, Michael M. Kitt, James E. Tcheng	2004	10
12	Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: An ESPRIT substudy American Heart Journal ·C. Michael Gibson, Sabina A. Murphy, Susan J. Marble, (unknown), Eric A. Cohen, Henry Lui, John K. Young, Michael M. Kitt, Todd J. Lorenz, James E. Tcheng	2002	33
13	Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial) The American Journal of Cardiology ·Marino Labinaz, Mina Madan, J.Conor O’Shea, Rakhi Kilaru, Wai Chin, Karen S. Pieper, Darren K. McGuire, Jorge F. Saucedo, J. David Talley, María Alejandra Patiño Giraldo, Michael M. Kitt, Robert M. Califf, James E. Tcheng	2002	18
14	Combination Reperfusion Therapy with Eptifibatide and Tenecteplase for Acute Myocardial Infarction Matthew T. Roe, Robert P. Giugliano, Robert A. Harrington, C. Michael Gibson, John Strony, Michael M. Kitt, Robert M. Califf, Eugene Braunwald	2001	5
15	Effect of eptifibatide on coronary flow reserve following coronary stent implantation (An ESPRIT substudy) The American Journal of Cardiology ·C. Michael Gibson, (unknown), Eric A. Cohen, Henry Lui, Sabina A. Murphy, Susan J. Marble, Michael M. Kitt, Todd J. Lorenz, James E. Tcheng	2001	29
16	Platelet Glycoprotein IIb/IIIa Integrin Blockade With Eptifibatide in Coronary Stent Intervention JAMA ·J.Conor O’Shea, Gail E. Hafley, Sally Greenberg, Vic Hasselblad, Todd J. Lorenz, Michael M. Kitt, John Strony, James E. Tcheng, Hans Blomkvist	2001	160
17	Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II) The American Journal of Cardiology ·Hanxing Yang, Robert M. Califf, Barbara E. Tardiff, Laura H. Gardner, Kristina N. Sigmon, A. Michael Lincoff, Eric J. Topol, Michael M. Kitt, James C. Blankenship, James E. Tcheng	2000	36
18	Comparison of receptor occupancy and platelet aggregation response of eptifibatide administered intravenously in patients with unstable angina or non-Q-wave myocardial infarction Journal of the American College of Cardiology ·Lisa K. Jennings, Barbara E. Tardiff, David R. Phillips, Robert M. Scarborough, Michael M. Kitt, Daniel D. Gretler	1998	3
19	Maximal benefit of integrelin platelet IIB/IIIa blockade 6–24 hours after therapy: Results of the IMPACT-II trial Journal of the American College of Cardiology ·M. Horrigan, James E. Tcheng, Robert M. Califf, Michael M. Kitt, Todd J. Lorenz, Kristina N. Sigmon, A. Michael Lincoff, Eric J. Topol	1996	5
20	Integrelin for emergency coronary artery stenting Journal of the American College of Cardiology ·James P. Zidar, 武士菊池, Hanxing Yang, Dean J. Kereiakes, Joseph B. Muhlestein, Charles J. Davidson, Paul S. Teirstein, Alan N. Tenaglia, Steven J. Yakubov, Jeffrey J. Popma, Jean‐François Tanguay, Michael M. Kitt, Todd J. Lorenz, James E. Tcheng, A. Michael Lincoff, Mekala Sachith Reddy, Eric J. Topol	1996	13

About Michael M. Kitt

Michael M. Kitt is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine, Clinical Biochemistry, Emergency Medical Services and Gastroenterology, having authored 84 papers that have together received 4.0k indexed citations. Recurring topics across this work include Acute Myocardial Infarction Research (30 papers), Antiplatelet Therapy and Cardiovascular Diseases (24 papers), Respiratory and Cough-Related Research (17 papers), Antimicrobial Resistance in Staphylococcus (14 papers), Coronary Interventions and Diagnostics (14 papers), Heparin-Induced Thrombocytopenia and Thrombosis (9 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Pediatric health and respiratory diseases (8 papers). The work is most often cited by research in Internal Medicine (517 citations), Cardiology and Cardiovascular Medicine (2.0k citations), Clinical Biochemistry (509 citations), Infectious Diseases (910 citations) and Molecular Medicine (219 citations). Michael M. Kitt has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Steven L. Barriere, Eric J. Topol, James E. Tcheng, Robert A. Harrington, A. Michael Lincoff, Neal S. Kleiman, Kristina N. Sigmon, Michael R. Goldberg, G. Ralph Corey and Martín E. Stryjewski. Their work appears in journals such as The American Journal of Cardiology, Journal of the American College of Cardiology, Circulation, Antimicrobial Agents and Chemotherapy and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact